[1]王浩南,曹 军.腹腔热灌注化疗治疗进展期胃癌疗效及安全性分析[J].陕西医学杂志,2022,51(12):1560-1563.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.022]
　WANG Haonan,CAO Jun.Efficacy and safety of hyperthermic intraperitoneal chemotherapy for advanced gastric cancer[J].,2022,51(12):1560-1563.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.022]
点击复制

腹腔热灌注化疗治疗进展期胃癌疗效及安全性分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年12期
页码:
1560-1563
栏目:
临床研究
出版日期:
2022-12-05

文章信息/Info

Title:
Efficacy and safety of hyperthermic intraperitoneal chemotherapy for advanced gastric cancer
作者:
王浩南1; 曹 军2
(1.西安交通大学第一附属医院肿瘤外科,陕西 西安 710061; 2.西安医学院第三附属医院肿瘤科,陕西 西安 710068)
Author(s):
WANG Haonan; CAO Jun
(Department of Surgical Oncology,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
关键词:
进展期胃癌;  腹腔热灌注化疗;  围手术期;  肿瘤标志物;  安全性
Keywords:
Advanced gastric cancer;  Hyperthermic intraperitoneal chemotherapy;  Peroperative period;  Turmor marker;  Safety
分类号:
R 735.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.12.022
文献标志码:
A
摘要:
目的:探讨腹腔热灌注化疗(HIPEC)治疗进展期胃癌的疗效及安全性。方法:选取接受手术治疗的进展期胃癌患者79例为研究对象,均已经病理检查确诊,随机分为观察组(36例)和对照组(43例)。观察组接受手术联合HIPEC治疗,对照组仅进行手术及术后辅助治疗。比较两组围手术期指标、肿瘤标志物指标、术后胃癌复发转移及患者生存情况。结果:观察组腹痛、骨髓抑制、消化道症状占比高于对照组(均P<0.05)。术前两组癌胚抗原(CEA)和糖类抗原199(CA199)水平比较差异无统计学意义(均P>0.05),化疗6周期后观察组CEA水平低于对照组(P<0.05),CA199水平与对照组比较差异无统计学意义(P>0.05)。术后1年内,观察组患者吻合口、原发灶、腹腔内复发占比低于对照组(P<0.05),肝、肺等远处转移以及病死率与对照组比较差异无统计学意义(均P>0.05)。结论:HIPEC可协同术后辅助化疗,安全、有效地改善进展期胃癌患者的术后生存状态,降低血清CEA水平,减少术区局部复发率。
Abstract:
Objective:To investigate the efficacy and safety of hyperthermic intraperitoneal chemotherapy(HIPEC)for advanced gastric cancer.Methods:Seventynine patients with advanced gastric cancer who underwent surgery were included in the study,all of whom had a pathological diagnosis,and were randomly divided into observation group(36 cases)and control group(43 cases).The observation group received surgery in combination with HIPEC,and the control group underwent surgery and postoperative adjuvant therapy.Perioperative parameters,tumor markers,recurrence and metastasis of gastric cancer,and patient survival were compared between the two groups.Results:The proportions of abdominal pain,bone marrow depression,and gastrointestinal symptoms were higher in the observation group than those in the control group(all P<0.05).Before operation,there was no significant difference in the levels of CEA and CA199 between two groups(all P>0.05); after 6 cycles of chemotherapy,the CEA level in the observation group was lower than that in the control group(P<0.05),but there was no significant difference in CA199 level between two groups(P>0.05).Conclusion:HIPEC can cooperate with adjuvant chemotherapy,safely and effectively improve postoperative survival in patients with advanced gastric cancer,reduce serum CEA level,and reduce local recurrence rate in the surgical field.

参考文献/References:

[1] Zheng R,Zhang S,Zeng H,et al.Cancer incidence and mortality in China,2016[J].Journal of the National Cancer Center,2022,1(2):1-9.
[2] 唐鸿生,崔书中,唐云强,等.腹腔热灌注化疗治疗晚期胃癌合并腹水的临床疗效观察[J].消化肿瘤杂志:电子版,2013,5(1):26-32.
[3] Yang XJ,Huang CQ,Suo T,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase Ⅲ randomized clinical trial[J].Ann Surg Oncol,2011,18(6):1575-1581.
[4] Li Y.My standpoint of perioneal carcinomatosis study[J].J Clin Oncol,2012,39(22):1685-1686.
[5] 李 雁,周云峰,谢丛华,等.细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移癌的临床研究[J].肿瘤防治研究,2016,43(4):1734-1740.
[6] 姬忠贺,李 雁.肿瘤细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移的现状与前景[J].外科理论与实践,2021,26(1):11-16.
[7] 姜瑞涛,王玉彬,王贵军.洛铂、雷替曲塞在进展期胃癌术后患者腹腔热灌注化疗中的安全性对比观察[J].山东医药,2021,61(9):70-73.
[8] 柏巍松,申 力,唐纪全,等.术中腹腔热灌注化疗联合全腹腔镜下胃癌D2根治术治疗胃癌的临床分析[J].肿瘤研究与临床,2021,33(11):834-839.
[9] Glehen O,Passot G,Villeneuve L,et al.GASTRICHIP: D2 resection and hyperthermic ntraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase Ⅲ study[J].BMC Cancer,2014,14:183.
[10] Quenet F,Elias D,Roca L,et al.A unicancer phase Ⅲ trial of hyperthermic intraperitoneal chemotherapy(HIPEC)for colorectal peritoneal carcinomatosis(PC):PRODIGE 7[J].J Clin Oncol,2018,36(18_Suppl):3503.
[11] 魏海梁,李京涛,周 军.进展期胃癌术后腹腔热灌注化疗的临床研究[J].陕西医学杂志,2015,44(8):1055-1057.
[12] 张晶晶,岳丽娟,王 莹,等.奥拉帕利联合奈达铂腹腔热灌注化疗治疗上皮性卵巢癌疗效观察[J].陕西医学杂志,2021,50(12):1566-1569.
[13] 孔宪诚,黄建平,阎 良,等.腹腔热灌注化疗治疗不同Borrmann分型进展期胃癌的临床效果及对肿瘤标志物的影响[J].中国肿瘤外科杂志,2021,13(4):372-376.
[14] 庞芳宁,白 槟,杨 鹏,等.肿瘤标志物CEA、CA199、CA125联合检测对胃癌筛查价值及与TNM分期的关系[J].陕西医学杂志,2020,49(8):1040-1044.
[15] Mattar R,Alves Deandrade CR,Difavero GM,et al.Preoperative serum levels of CA724,CEA,CA199,and alpha-fetoprotein in patients with gastric cancer[J].Rev Hosp Clin Fac Med Sao Paulo,2002,57(3):89-92.
[16] 唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究[J].陕西医学杂志,2019,48(4):435-437,441.
[17] 袁泽伟,孙 敏,向真贤,等.腹腔热灌注联合全身化疗治疗胃癌恶性腹水的疗效和安全性Meta分析[J].现代肿瘤医学,2018,26(7):2094-2099.
[18] 陈心足,周总光,胡建昆,等.胃癌和结直肠癌腹腔热灌注化疗的欧洲临床试验进展[J].华西医学,2018,33(12):1460-1465.
[19] 安松林,张 凯,姬忠贺,等.肿瘤细胞减灭术联合腹腔热灌注化疗治疗结直肠癌腹膜癌的疗效[J].中华肿瘤杂志,2021,43(12):1298-1303.
[20] 詹宏杰,梁 寒.腹腔热灌注化疗在腹膜癌中的应用现状[J].肿瘤防治研究,2021,48(4):327-332.

相似文献/References:

[1]余 伟,高怀军△.腹腔镜与传统开腹根治术治疗进展期胃癌临床效果对比研究*[J].陕西医学杂志,2019,(11):1471.
　YU Wei,GAO Huaijun.Clinical study of laparoscopic radical resection and traditional open radical resection with advanced gastric cancer[J].,2019,(12):1471.
[2]张晶晶,岳丽娟,王 莹,等.奥拉帕利联合奈达铂腹腔热灌注化疗治疗上皮性卵巢癌疗效观察[J].陕西医学杂志,2021,50(12):1566.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.025]
　ZHANG Jingjing,YUE Lijuan,WANG Ying,et al.Efficacy of olaparib combined with nedaplatin hyperthermic intraperitoneal chemotherapy in treatment of epithelial ovarian cancer[J].,2021,50(12):1566.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.025]
[3]赵天号,张银旭.雷替曲塞腹腔热灌注化疗联合D2根治性胃切除术治疗局部进展期胃癌疗效和安全性研究[J].陕西医学杂志,2022,51(11):1428.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.026]

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基础研究计划项目(2021JM-263)
更新日期/Last Update: 2022-12-05